CAJ | 학술논문

目的通过meta分析研究胃癌D2根治术后辅助化疗对患者预后的影响.方法应用Pubmed、Cochrane、Embase和中国生物医学文献数据库检索1990-2012年发表的关于胃癌D2根治术后进行辅助化疗与单纯行D2根治术对比的随机对照研究,试验质量采用Jadad量表检验,用RevMan 5.1软件进行meta分析研究术后辅助化疗对患者预后的影响.结果共检索出相关文献314篇,最后符合纳入标准的8篇,共纳入3633例患者,其中化疗组1824例,对照组1809例.化疗组总体生存率(RR =0.76,95％ CI:0.69 ～0.84)及无病生存率(RR =0.72,95％CI:0.66～0.80)高于对照组,复发率低于对照组(RR=0.69,95％CI:0.62～0.77).结论胃癌D2根治术后行辅助化疗可以提高患者总体生存率及无病生存率,降低复发率.
목적 통과meta분석연구위암D2근치술후보조화료대환자예후적영향.방법 응용Pubmed、Cochrane、Embase화중국생물의학문헌수거고검색1990-2012년발표적관우위암D2근치술후진행보조화료여단순행D2근치술대비적수궤대조연구,시험질량채용Jadad량표검험,용RevMan 5.1연건진행meta분석연구술후보조화료대환자예후적영향.결과 공검색출상관문헌314편,최후부합납입표준적8편,공납입3633례환자,기중화료조1824례,대조조1809례.화료조총체생존솔(RR =0.76,95％ CI:0.69 ～0.84)급무병생존솔(RR =0.72,95％CI:0.66～0.80)고우대조조,복발솔저우대조조(RR=0.69,95％CI:0.62～0.77).결론 위암D2근치술후행보조화료가이제고환자총체생존솔급무병생존솔,강저복발솔.
Objective To evaluate efficacy of adjuvant chemotherapy after D2 dissection on survival for patients with gastric cancer.Methods Randomized clinical trials (RCT) that compared adjuvant chemotherapy after D2 dissection with D2 dissection alone for gastric cancer were searched with Pubmed,Cochrane,Embase and CBM databases.Eligible trials published between 1990 and 2012 were included in the study.The quality of RCTs was assessed by the Jadad scale.Data synthesis and statistical analysis were performed by RevMan 5.1 software.Results Eight RCTs with 3633 patients were included in this study.Among them,1824 patients received adjuvant chemotherapy and 1809 patients didn' t.Adjuvant chemotherapy was associated with a significant benefit in terms of overall survival (RR =0.76,95％ CI:0.69-0.84),disease free survival (RR =0.72,95％ CI:0.66-0.80) and recurrence rate (RR =0.69,95％ CI:0.62-0.77).Conclusion Adjuvant chemotherapy was associated with survival benefit for gastric cancer after D2 dissection.